Coherus BioSciences, Inc. (CHRS): Price and Financial Metrics

Coherus BioSciences, Inc. (CHRS)

Today's Latest Price: $18.41 USD

0.42 (2.33%)

Updated Sep 25 4:00pm

Add CHRS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

CHRS Stock Summary

  • In terms of twelve month growth in earnings before interest and taxes, Coherus BioSciences Inc is reporting a growth rate of -296.37%; that's higher than merely 6.38% of US stocks.
  • Revenue growth over the past 12 months for Coherus BioSciences Inc comes in at 304.37%, a number that bests 97.88% of the US stocks we're tracking.
  • The volatility of Coherus BioSciences Inc's share price is greater than that of merely 8.73% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to CHRS, based on their financial statements, market capitalization, and price volatility, are ACMR, SMLR, CPAH, AAT, and TAST.
  • CHRS's SEC filings can be seen here. And to visit Coherus BioSciences Inc's official web site, go to
CHRS Daily Price Range
CHRS 52-Week Price Range

CHRS Stock Price Chart Technical Analysis Charts

CHRS Price/Volume Stats

Current price $18.41 52-week high $23.06
Prev. close $17.99 52-week low $10.86
Day low $17.99 Volume 575,271
Day high $18.68 Avg. volume 1,354,268
50-day MA $18.73 Dividend yield N/A
200-day MA $18.01 Market Cap 1.32B

Coherus BioSciences, Inc. (CHRS) Company Bio

Coherus Biosciences is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. The company was founded in 2010 and is based in Redwood City, California.

CHRS Latest News Stream

Event/Time News Detail
Loading, please wait...

CHRS Latest Social Stream

Loading social stream, please wait...

View Full CHRS Social Stream

Latest CHRS News From Around the Web

Below are the latest news stories about Coherus BioSciences Inc that investors may wish to consider to help them evaluate CHRS as an investment opportunity.

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective September 17, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 118,000 shares of the common stock of the Company to six newly hired non-officer employees, with a per share exercise price of $19.07, the closing trading price on the grant date. A Vice President was also granted an option to purchase 45,000 shares of the Company’s common stock, with a per share exercise price of $19.07, the closing trading price on the grant date.The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the...

Yahoo | September 18, 2020

Coherus Has A High-Quality Business Model And Good Long-Term Potential

Coherus Biosciences (CHRS) is a company that develops and markets biosimilar versions of popular biologics that have been out on the market for years with typically high levels of sales. Coherus has built an impressive level of cash flow already, yet shares trade for just over 2.5x this year’s expected...

Andy Jones on Seeking Alpha | September 13, 2020

Our View On Coherus BioSciences' (NASDAQ:CHRS) CEO Pay

Denny Lanfear has been the CEO of Coherus BioSciences, Inc. (NASDAQ:CHRS) since 2010, and this article will examine...

Yahoo | September 13, 2020

Coherus BioSciences' (CHRS) CEO Denny Lanfear on Q2 2020 Results - Earnings Call Transcript

Coherus BioSciences, Inc. (CHRS) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants David Arrington – Vice President-Investor Relations and Corporate Affairs Denny Lanfear – Chief Executive Officer Jean Viret – Chief Financial Officer Chris Thompson – Executive Vice President-Sales Conference Call Participants Mike Ulz –...

SA Transcripts on Seeking Alpha | August 8, 2020

Coherus BioSciences Reports Second Quarter 2020 Financial Results

– Second Quarter UDENYCA® Net Sales of $135.7 Million –– Net Income of $59.0 Million –– Non-GAAP Net Income of $68.3 Million – REDWOOD CITY, Calif.,…

GlobeNewswire | August 6, 2020

Read More 'CHRS' Stories Here

CHRS Price Returns

1-mo -2.95%
3-mo 6.72%
6-mo 9.65%
1-year -10.11%
3-year 38.42%
5-year -18.14%
YTD 2.25%
2019 98.95%
2018 2.84%
2017 -68.74%
2016 22.60%
2015 40.69%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8197 seconds.